Lantern Pharma INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Lantern Pharma reported a net loss of $10.4 million for the first six months of 2026, highlighting substantial doubt about its ability to continue as a going concern without significant additional funding.
NASDAQ
Lantern Pharma reports Q1 2026 financial results and announces plans to spin off its withZeta.ai platform into an independent entity.
NASDAQ
Lantern Pharma reported a narrower net loss in Q3 2025 and advanced its drug pipeline, but faces a going concern risk and requires substantial additional funding.
NASDAQ
Lantern Pharma Inc. reported a reduced net loss in Q2 2025 but faces substantial doubt about its ability to continue as a going concern due to significant cash burn and declining liquidity.
NASDAQ
10-Q: Lantern Pharma Reports Q1 2025 Financial Results, Highlights AI-Driven Drug Development Progress
Lantern Pharma Inc. announces its Q1 2025 financial results, emphasizing the continued advancement of its AI-driven RADR platform and clinical programs.
NASDAQ
Lantern Pharma reported a net loss of $4.5 million for the third quarter of 2024, while advancing its clinical programs and research initiatives.
NASDAQ
Lantern Pharma reported a net loss of $10.4 million for the first half of 2024, while advancing its clinical programs and research initiatives.
NASDAQ
Lantern Pharma reported a net loss of $5.4 million for the first quarter of 2024, while advancing its clinical programs and AI-driven drug discovery platform.